ROCKAWAY, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, announced today that gammaCore therapy will continue ...

ROCKAWAY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness ...

A study published in the Journal of Headache and Pain, carried out by Dr. Thomas Kinfe of the University of Bonn, found that twice daily stimulation of the vagus nerve with the hand-held gammaCore ...

The device, which just received approval from the U.S. Food and Drug Administration (FDA), is called GammaCore. People who suffer from a severe form of headache called cluster headaches now have a new ...

electroCore, Inc. (ECOR) is a producer of nVNS (non-invasive Vagus Nerve Stimulation) devices. These come in three flavors for different markets: Vagus nerve stimulation helps to restore the balance ...

electroCore's gammaCore non-invasive vagus nerve stimulation (nVNS) therapy improves quality of life when added to standard of care (SOC) gammaCore is cost-effective compared to other treatment ...

electroCore, Inc. announced promising data on the effectiveness of its gammaCore non-invasive vagus nerve stimulation (nVNS) device for treating concussive symptoms associated with mild traumatic ...

Noninvasive vagus nerve stimulation (nVNS)—using a handheld device that delivers a mild electrical current through the skin of the neck in two-minute applications that stimulate the vagus nerve—was ...

A team of scientists and researchers at Springfield, Mo..-based Jordan Valley Innovation Center and Missouri State are testing a device that could develop into a nonopioid pain relief treatment, ...

BASKING RIDGE, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company has received Section 510(k ...